ArticleScientific reports2026
Multifunctional hierarchical Ni
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The global rise of multidrug-resistant infections and cancer underscores the need for multifunctional therapeutic platforms. This study presents the synthesis, optimization, and biomedical assessment of sonicated hierarchical Ni₂CoS₄ structures, with sample N3 identified as optimal among seven hydrothermally synthesized formulations. N3 exhibited uniform morphology, high crystallinity, and redox-active architecture, as confirmed by XRD, SEM, TEM, and BET (8.19 m²/g). Piezocatalytic performance, assessed via methylene blue degradation, showed 88.57% removal within 4 min under 200 W ultrasonication, alongside a 13.27-fold increase in singlet oxygen and superoxide generation. N3 displayed potent antibacterial activity against MDR Staphylococcus aureus and XDR Pseudomonas aeruginosa, with minimum inhibitory concentrations as low as 5 µg/mL and complete bacterial clearance within 48 h. ROS-mediated membrane disruption and > 99% biofilm eradication were confirmed by DiBAC₄(3), TEM, and comparative assays with non-sonicated controls. In colorectal cancer (HCT-116) models, N3 induced dose-dependent cytotoxicity (IC₅₀ = 100 µg/mL; 91% cell death at LC₅₀) with sustained effects over 96 h. These findings position N3 as a promising ROS-generating platform with dual antimicrobial and anticancer efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.